Literature DB >> 23339136

Renal deterioration in multiple sclerosis patients with neurovesical dysfunction.

Sophie G Fletcher1, Benjamin E Dillon, Alienor S Gilchrist, Rashel M Haverkorn, Jingsheng Yan, Elliot M Frohman, Gary E Lemack.   

Abstract

OBJECTIVES: Our aims were to determine the prevalence of renal ultrasound (RUS) abnormalities over time in multiple sclerosis (MS) patients with lower urinary tract symptoms (LUTS).
METHODS: Data were examined retrospectively from MS patients with LUTS, from 2000-2009. Study inclusion requirements were both baseline urodynamics (UD) and RUS data, with followup RUS at ≥ 12 months. Age, time since diagnosis (TSD), MS subtype and the UD/RUS results were evaluated for associations.
RESULTS: At presentation, 173 subjects underwent UD and RUS, but only 89 had a repeat RUS at ≥ 12 months. Median followup was 61 months. Initial RUS abnormalities were found in 10 (5.8%) subjects. At followup, upper urinary tract (UUT) abnormalities were seen in 11 (12.4%) subjects. Patients > 49 years old were more likely to have an abnormality (OR 0.181, 95% CI 0.037-0.892, p = 0.04). Patients with abnormal compliance were also more likely to have an abnormal followup RUS (OR 0.185, 95% CI 0.037-0.924, p = 0.04). No other demographic or UD factor was associated with RUS abnormalities.
CONCLUSIONS: The development of structural UUT changes is low in MS patients. Urodynamic studies are useful for LUTS treatment strategies in complicated patients, but UD does not appear to have much impact with regard to upper tract changes.

Entities:  

Keywords:  Neurogenic bladder; lower urinary tract; multiple sclerosis; upper urinary tract; urodynamics; urological symptoms

Mesh:

Year:  2013        PMID: 23339136     DOI: 10.1177/1352458512474089

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  7 in total

Review 1.  Urodynamics: examining the current role of UDS testing. What is the role of urodynamic testing in light of recent AUA urodynamics and overactive bladder guidelines and the VALUE study?

Authors:  Elizabeth Timbrook Brown; Ryan M Krlin; J Christian Winters
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

2.  Overactive bladder symptoms in patients with multiple sclerosis: Frequency, severity, diagnosis and treatment.

Authors:  Yeşim Akkoç; Murat Ersöz; Nur Yüceyar; Hakan Tunç; Kurtuluş Köklü; Tahir Kurtuluş Yoldaş; Ülkü Dönmez; Cihat Uzunköprü; Ebru Alemdaroğlu; Şule Bilen; Ufuk Emre; Şenay Özdolap; Elif Tuncay; Canan Yücesan; Haydar Gök; Merve Bahar Ercan; Kürşat Uygunol; Belgin Koçer; Murat Zinnuroğlu
Journal:  J Spinal Cord Med       Date:  2016-02-15       Impact factor: 1.985

3.  Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Executive summary.

Authors:  Alex Kavanagh; Richard Baverstock; Lysanne Campeau; Kevin Carlson; Ashley Cox; Duane Hickling; Genviève Nadeau; Lynn Stothers; Blayne Welk
Journal:  Can Urol Assoc J       Date:  2019-06       Impact factor: 1.862

Review 4.  Surveillance urodynamics for neurogenic lower urinary tract dysfunction: A systematic review.

Authors:  Alex Kavanagh; Hamed Akhavizadegan; Matthias Walter; Lynn Stothers; Blayne Welk; Timothy B Boone
Journal:  Can Urol Assoc J       Date:  2018-12-03       Impact factor: 1.862

Review 5.  Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies.

Authors:  John T Stoffel
Journal:  Transl Androl Urol       Date:  2016-02

Review 6.  Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms.

Authors:  James M Tracey; John T Stoffel
Journal:  Investig Clin Urol       Date:  2016-10-24

7.  Preliminary Analysis of Brain Footprints in Multiple Sclerosis Females With Detrusor Sphincter Dyssynergia: A Concurrent Urodynamic and Functional Magnetic Resonance Imaging Study.

Authors:  Khue Tran; Logan Hubbard; Christof Karmonik; Timothy B Boone; Rose Khavari
Journal:  Int Neurourol J       Date:  2021-12-02       Impact factor: 2.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.